Oral anticoagulants in chronic kidney disease

Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation.

Atrial fibrillation (AF) is the most frequent arrhythmia in common clinical practice and its prevalence is markedly increased among patients with chronic kidney disease (CKD). The presence of CKD increases the incidence of AF and vice versa. Both AF and CKD increase the risk of stroke or systemic thromboembolism and oral anticoagulation is the mainstay for thromboembolic event prevention in pat...

Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations

Many patients with chronic kidney disease (CKD) receive anticoagulation or antiplatelet therapy due to atrial fibrillation, coronary artery disease, thromboembolic disease, or peripheral artery disease. The treatment usually includes vitamin K antagonists (VKAs) and/or platelet aggregation inhibitors. The direct oral anticoagulants (DOAC) inhibiting factor Xa or thrombin represent an alternativ...

Vitamin deficiencies in chronic kidney disease

Endocrine disorders in chronic kidney disease

Background and Objective: Endocrine disorders are common in patients with chronic kidney disease (CKD). The aim of the present study is reviewing available literature to give a deep understanding of complexities of endocrine disorders in chronic kidney disease. Methods: A narrative reviewing method based on the available literature was approached. Findings: Generally, when renal function de...

Oral antiplatelet agents and chronic kidney disease.

C hronic kidney disease (CKD) is recognized as an independent predictor for myocardial infarction, stroke and all-cause mortality due to accelerated atherosclerosis. Cardiovascular mortality accounts for 45% of allcause mortality in CKD patients, while in end-stage renal disease (ESRD) death attributable to arrhythmic mechanisms is responsible for 27% of the cardiovascular mortality observed in...